HK1250378B - T cell expansion - Google Patents

T cell expansion Download PDF

Info

Publication number
HK1250378B
HK1250378B HK18108568.5A HK18108568A HK1250378B HK 1250378 B HK1250378 B HK 1250378B HK 18108568 A HK18108568 A HK 18108568A HK 1250378 B HK1250378 B HK 1250378B
Authority
HK
Hong Kong
Prior art keywords
cells
virus
culture
media
peptide
Prior art date
Application number
HK18108568.5A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1250378A1 (en
Inventor
Peter Wang
Chunxiao Wu
Original Assignee
Tessa Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tessa Therapeutics Ltd. filed Critical Tessa Therapeutics Ltd.
Publication of HK1250378A1 publication Critical patent/HK1250378A1/en
Publication of HK1250378B publication Critical patent/HK1250378B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK18108568.5A 2016-05-24 2016-10-25 T cell expansion HK1250378B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340605P 2016-05-24 2016-05-24
US201662340605P 2016-05-24
US201615290230 2016-10-11
US15/290,230 US10052372B2 (en) 2016-05-24 2016-10-11 T cell expansion
PCT/EP2016/075644 WO2017202478A1 (en) 2016-05-24 2016-10-25 T cell expansion

Publications (2)

Publication Number Publication Date
HK1250378A1 HK1250378A1 (en) 2018-12-14
HK1250378B true HK1250378B (en) 2020-05-08

Family

ID=57886334

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108568.5A HK1250378B (en) 2016-05-24 2016-10-25 T cell expansion

Country Status (12)

Country Link
US (2) US10052372B2 (cg-RX-API-DMAC10.html)
EP (1) EP3265555B1 (cg-RX-API-DMAC10.html)
JP (1) JP2019520061A (cg-RX-API-DMAC10.html)
KR (1) KR20190013831A (cg-RX-API-DMAC10.html)
CN (1) CN109563483A (cg-RX-API-DMAC10.html)
DK (1) DK3265555T3 (cg-RX-API-DMAC10.html)
ES (1) ES2742215T3 (cg-RX-API-DMAC10.html)
HK (1) HK1250378B (cg-RX-API-DMAC10.html)
PT (1) PT3265555T (cg-RX-API-DMAC10.html)
SG (1) SG11201810471YA (cg-RX-API-DMAC10.html)
TW (1) TWI660970B (cg-RX-API-DMAC10.html)
WO (1) WO2017202478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972227T3 (es) * 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
JP6987080B2 (ja) 2016-05-05 2021-12-22 サウスウェスト リサーチ インスティテュート 細胞増殖のための三次元バイオリアクター及び関連用途
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
KR102150371B1 (ko) * 2017-05-06 2020-09-01 엘지전자 주식회사 무선 통신 시스템에서 단말의 d2d 동작 방법 및 상기 방법을 이용하는 단말
EP3723774A4 (en) * 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
US11447731B2 (en) 2018-09-24 2022-09-20 Southwest Research Institute Three-dimensional bioreactors
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
WO2022197933A1 (en) 2021-03-18 2022-09-22 The Broad Institute, Inc. Compositions and methods for characterizing lymphoma and related conditions
JP2024515803A (ja) 2021-04-27 2024-04-10 ベイラー カレッジ オブ メディスン キメラ抗原受容体を発現するウイルス特異的免疫細胞
EP4422787A1 (en) 2021-10-28 2024-09-04 Southwest Research Institute Devices for cell separation
TW202346576A (zh) 2022-04-13 2023-12-01 新加坡商泰莎治療有限公司 治療性t細胞產品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
AU1220599A (en) 1997-11-14 1999-06-07 Hemosol Inc. Method for the production and use of dendritic cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
WO2011072088A2 (en) * 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
BR112014014591A8 (pt) * 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
JP6327734B2 (ja) * 2012-03-07 2018-05-23 国立大学法人富山大学 Ｔ細胞の刺激方法およびその利用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Also Published As

Publication number Publication date
KR20190013831A (ko) 2019-02-11
DK3265555T3 (da) 2019-08-12
US20170028042A1 (en) 2017-02-02
US10052372B2 (en) 2018-08-21
CN109563483A (zh) 2019-04-02
EP3265555A1 (en) 2018-01-10
TW201741330A (zh) 2017-12-01
PT3265555T (pt) 2019-09-04
SG11201810471YA (en) 2018-12-28
EP3265555B1 (en) 2019-05-22
US20190269768A1 (en) 2019-09-05
JP2019520061A (ja) 2019-07-18
TWI660970B (zh) 2019-06-01
WO2017202478A1 (en) 2017-11-30
ES2742215T3 (es) 2020-02-13

Similar Documents

Publication Publication Date Title
EP3265555B1 (en) T cell expansion
HK1250378A1 (en) T cell expansion
US20200172864A1 (en) T Cell Expansion Method
ES2765884T3 (es) Métodos de expansión y evaluación de linfocitos B y uso de linfocitos B expandidos para el tratamiento de enfermedades
JP6010136B2 (ja) ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
EP3666888A2 (en) Method for activating t cells for cancer treatment
KR20190051039A (ko) 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼
JP5016489B2 (ja) 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
US11944672B2 (en) Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying Treg cells to produce therapeutic vaccine for treatment of diabetes type 1
JP6018081B2 (ja) 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞
JP6697076B2 (ja) ウイルス抗原特異的ｔ細胞の濃縮および拡大方法
Alici et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
JP2019520823A (ja) メモリーｔ細胞から作られるベト細胞
TW202104245A (zh) Ebv特異性免疫細胞
CN101258238A (zh) 抗原呈递细胞的活化处理方法
JP2025106402A (ja) がん治療のためのｔ細胞の活性化方法
CN113521270A (zh) 一种ebv复合抗原、树突状细胞疫苗及其应用
CN1230204C (zh) 通过继承性转运抗原特异性的细胞毒t细胞建立的免疫调节方法
WO2026070936A1 (ja) 抗原特異的ｔ細胞の製造方法、および製造用キット
CN117604011A (zh) 融合基因、表达该融合基因的滋养型树突状细胞、自然杀伤细胞培养方法以及自然杀伤细胞
WO2005078072A1 (ja) Ｔ細胞免疫活性を調節する制御性細胞
Jalili et al. Sayahinouri M, Dehghani Ghorbi M, Roshandel E, Aghdami N. Virus-Specific T cells: Promising Adoptive T Cell Therapy against Infectious Diseases following Hematopoietic
JP2003321375A (ja) ヒトｔ細胞による肝疾患治療剤

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231024